Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Summary
Bill A03833 mandates that all insurance policies covering prescription drugs must provide coverage for FDA-approved antiviral therapeutics for COVID-19, prescribed by licensed healthcare providers. The bill specifies that this coverage should not be subject to annual deductibles or coinsurance, ensuring that patients can access these treatments without additional financial burdens. Furthermore, if patients can obtain these therapeutics at no cost through manufacturer or government programs, they must utilize those options before accessing insurance coverage.
Impact
This legislation will significantly alter the landscape of health insurance coverage in New York by ensuring that antiviral COVID-19 treatments are accessible without out-of-pocket costs. It amends existing insurance laws to include specific provisions for antiviral therapeutics, thereby reinforcing the state's commitment to public health and the management of COVID-19. The bill will affect insurance companies, health service corporations, and medical assistance programs, compelling them to adapt their policies to comply with the new requirements.
Sentiment
The sentiment surrounding Bill A03833 appears to be generally supportive, as it addresses a critical public health need by ensuring access to antiviral treatments for COVID-19. However, there may be concerns regarding the financial implications for insurance providers and the potential for increased premiums as a result of mandated coverage.
Contention
Points of contention may arise from insurance companies regarding the financial impact of providing this coverage without deductibles or coinsurance. Some stakeholders may argue that this could lead to increased costs for insurers, which may ultimately be passed on to consumers through higher premiums. Additionally, there may be discussions about the necessity of requiring patients to utilize existing manufacturer or government programs before accessing insurance coverage.
Same As
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Dementia treatment medical services and prescription medications coverage requirement provision and step therapy requirements for medical assistance provision
Coverage of medical services and prescription medications for the treatment of dementia required, and step therapy requirements for medical assistance modified.
Amends the current law on health insurance coverage for fertility diagnostic care, standard fertility preservation services, and fertility treatment and requires coverage for any medically necessary ovulation-enhancing drugs and medical services.
Establishes deadline for DEP implementation of prescribed burn program, and provides for establishment of prescribed burn acreage goals, schedules, calendars, training program, and mobile deployment units to provide on-site prescribed burn training and assistance.